research
A Blood Test Sorts Radium-223 Responders
Baseline and on-treatment circulating tumor DNA tracked outcomes in metastatic prostate cancer receiving bone-targeted radiotherapy.
Summary
Baseline and on-treatment circulating tumor DNA tracked outcomes in metastatic prostate cancer receiving bone-targeted radiotherapy.
Higher tumor-DNA burden and TP53, PTEN, or cell-cycle alterations were associated with worse outcomes, while changes during treatment reflected disease course. The study proposes a biomarker for selection and monitoring; it does not make the test a validated standard of care.
Why it matters
Baseline and on-treatment circulating tumor DNA tracked outcomes in metastatic prostate cancer receiving bone-targeted radiotherapy.
Limits and context
- The study proposes a biomarker for selection and monitoring; it does not make the test a validated standard of care.
Key claims
Baseline and on-treatment circulating tumor DNA tracked outcomes in metastatic prostate cancer receiving bone-targeted radiotherapy.
Qualification: The study proposes a biomarker for selection and monitoring; it does not make the test a validated standard of care.
Evidence: source-2026-07-19-018
Sources
- Society of Nuclear Medicine and Molecular Imaging: Radium-223 ctDNASociety of Nuclear Medicine and Molecular Imaging · secondary reporting
Corrections
No corrections have been recorded for this story.